What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The situation with compounded GLP-1s and the FDA is complex and has been a significant point of contention. Here's a breakdown:

What Happened with the FDA and Compounded GLP-1s?

When GLP-1 medications like Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide) gained massive popularity for weight loss and diabetes management, demand quickly outstripped supply. This led to many compounding pharmacies and some telehealth providers offering compounded versions of these drugs.

The FDA's primary concerns and actions have centered around several key issues:

1. Use of Unapproved Active Pharmaceutical Ingredients (APIs):

   • The FDA has explicitly stated that many compounded semaglutide and tirzepatide products have used salt forms of the drugs (like semaglutide sodium or semaglutide acetate) rather than the base form used in the FDA-approved products.
   • The FDA has not evaluated the safety or efficacy of these salt forms for compounding or for human use as GLP-1 medications. There's no scientific evidence that these salt forms are safe or effective.
   • This is a critical distinction: the FDA considers using these salt forms illegal and risky.

2. Lack of FDA Oversight and Quality Control:

   • Unlike FDA-approved drugs, compounded medications are not reviewed by the FDA for safety, efficacy, or manufacturing quality before they are marketed.
   • The FDA has raised concerns about the potential for contamination, incorrect dosages, and lack of sterility in some compounded products, leading to patient harm.

3. Misleading Marketing and Safety Claims:

   • Some compounders and providers have marketed their products in ways that suggest they are FDA-approved or equivalent to the approved drugs, which is false.

4. Circumventing Drug Shortage Rules:

   • Compounding is generally allowed by federal law only when there is a documented drug shortage of an FDA-approved drug or a specific patient needs a customized medication (e.g., due to an allergy to an inactive ingredient in the approved drug).
   • While Ozempic, Wegovy, Mounjaro, and Zepbound have been on the FDA's drug shortage list at various times, the FDA argues that this doesn't authorize the use of any version of semaglutide or tirzepatide, especially the unapproved salt forms. The shortage refers to the FDA-approved base form of the drug.

FDA Actions: The FDA has issued numerous warning letters to compounding pharmacies, telehealth platforms, and even individual prescribers. They've also taken legal action against some facilities and have consistently published consumer warnings against using these unapproved compounded versions.

Who Is Still Operating Legally?

Operating legally in the realm of compounded GLP-1s is very narrow and comes with strict conditions. Here's what's generally considered legal:

1. State-Licensed Compounding Pharmacies (503A Pharmacies):

   • Conditions: A state-licensed pharmacy can legally compound a GLP-1 medication ONLY IF:
     • There is a patient-specific prescription from a licensed healthcare provider.
     • The FDA-approved version of the drug is currently on the FDA's drug shortage list.
     • They use the FDA-approved API (the base form of semaglutide or tirzepatide), which is not one of the unapproved salt forms (like semaglutide sodium or semaglutide acetate).
     • They adhere to all state board of pharmacy regulations and USP (United States Pharmacopeia) compounding standards.
   • Key Point: If a compounding pharmacy is using semaglutide sodium or semaglutide acetate, they are not operating legally according to the FDA.

2. FDA-Registered Outsourcing Facilities (503B Facilities):

   • Conditions: These facilities are designed for larger-scale compounding and are subject to stricter FDA oversight (including Current Good Manufacturing Practices, cGMPs), similar to traditional drug manufacturers. They can prepare medications in bulk without patient-specific prescriptions in anticipation of demand.
   • Still, they must meet the same fundamental requirements as 503A pharmacies for GLP-1s:
     • The FDA-approved version must be on the FDA's drug shortage list.
     • They must use the FDA-approved API (the base form).
     • They must meet stringent quality and safety standards.
   • Recommendation: If you absolutely need a compounded medication (and your doctor determines it's appropriate), a 503B outsourcing facility is generally considered safer due to the increased FDA oversight.

Specific Recommendations for Consumers:

• Ask for the API: If you are considering a compounded GLP-1, explicitly ask your prescribing doctor or the compounding pharmacy for the exact Active Pharmaceutical Ingredient (API) they are using. If it's "semaglutide sodium" or "semaglutide acetate," it's not the FDA-approved API and carries significant risks according to the FDA. The legal and safe form would just be "semaglutide" or "tirzepatide" (the base form).
• Verify Shortage Status: Check the FDA's official drug shortage list (available on their website) to confirm if the specific FDA-approved GLP-1 you're interested in is actually in shortage.
• Consult Your Doctor: Always discuss the risks and benefits of compounded medications with your healthcare provider. They can help you determine if a compounded drug is appropriate for your specific medical needs and if they can recommend a reputable, compliant pharmacy.
• Be Skeptical of "Too Good To Be True" Offers: Extremely low prices or promises of guaranteed availability for compounded GLP-1s should raise red flags.

While compounding pharmacies serve a vital role in healthcare for specific patient needs, the FDA has made it clear that the vast majority of compounded GLP-1s offered using unapproved salt forms are not considered legal or safe. Your best bet is to pursue FDA-approved medications or, if medically necessary, work with a doctor and a reputable pharmacy using the FDA-approved base API under strict shortage conditions.